1. Pink Sheet

COVID-19 Vaccines: Novavax Gets Reprieve With US FDA Panel Supporting JN.1 Formulation

 
• By Sue Sutter

Advisory committee members said having Novavax’s protein-based vaccine available in the fall was important, but would not have been possible if a different variant strain were used. They also worried separate recommendations by vaccine type would cause confusion.

Tree trunk
A JN.1 vaccine will target the trunk of the tree, not the branches, a CDC official said. • Source: Shutterstock

The 2024-2025 formulations for COVID-19 vaccines should uniformly target the JN.1 variant, a US Food and Drug Administration advisory committee said, declining the agency’s invitation to suggest separate variant-based recommendations according to vaccine type.

Members of the Vaccines and Related Biological Products Advisory Committee unanimously voted in favor of a monovalent JN.1-lineage vaccine composition on 5 June. In a discussion question after the vote,...

Key Takeaways

  • The VRBPAC recommended the 2023-2024 formulations for all COVID-19 vaccines target the JN.1 variant.

  • The recommendation, if accepted by the FDA, means Novavax would...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from US FDA Performance Tracker

More from Regulatory Trackers